300 related articles for article (PubMed ID: 25963915)
1. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Kacan SB; Ozer H; Cetin A
Reprod Sci; 2015 Nov; 22(11):1445-51. PubMed ID: 25963915
[TBL] [Abstract][Full Text] [Related]
2. Effect of imatinib on growth of experimental endometriosis in rats.
Yildiz C; Kacan T; Akkar OB; Karakus S; Seker M; Kacan SB; Ozer H; Cetin A
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():159-63. PubMed ID: 26773307
[TBL] [Abstract][Full Text] [Related]
3. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Leconte M; Santulli P; Chouzenoux S; Marcellin L; Cerles O; Chapron C; Dousset B; Batteux F
Reprod Sci; 2015 Sep; 22(9):1171-80. PubMed ID: 26169036
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Stacchiotti S; Tortoreto M; Baldi GG; Grignani G; Toss A; Badalamenti G; Cominetti D; Morosi C; Dei Tos AP; Festinese F; Fumagalli E; Provenzano S; Gronchi A; Pennacchioli E; Negri T; Dagrada GP; Spagnuolo RD; Pilotti S; Casali PG; Zaffaroni N
Eur J Cancer; 2014 Nov; 50(17):3021-8. PubMed ID: 25269954
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
7. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Shantakumar S; Nordstrom BL; Djousse L; Hall SA; Gagnon DR; Fraeman KH; van Herk-Sukel M; Chagin K; Nelson J
Cancer Chemother Pharmacol; 2016 Sep; 78(3):559-66. PubMed ID: 27438066
[TBL] [Abstract][Full Text] [Related]
9. A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
Pauty J; Usuba R; Cheng IG; Hespel L; Takahashi H; Kato K; Kobayashi M; Nakajima H; Lee E; Yger F; Soncin F; Matsunaga YT
EBioMedicine; 2018 Jan; 27():225-236. PubMed ID: 29289530
[TBL] [Abstract][Full Text] [Related]
10. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Denorme M; Yon L; Roux C; Gonzalez BJ; Baudin E; Anouar Y; Dubessy C
Cancer Lett; 2014 Oct; 352(2):236-44. PubMed ID: 25016061
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
Ozer H; Boztosun A; AƧmaz G; Atilgan R; Akkar OB; Kosar MI
Reprod Sci; 2013 Jan; 20(1):26-32. PubMed ID: 22895024
[TBL] [Abstract][Full Text] [Related]
12. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Alfaro C; Suarez N; Gonzalez A; Solano S; Erro L; Dubrot J; Palazon A; Hervas-Stubbs S; Gurpide A; Lopez-Picazo JM; Grande-Pulido E; Melero I; Perez-Gracia JL
Br J Cancer; 2009 Apr; 100(7):1111-9. PubMed ID: 19277038
[TBL] [Abstract][Full Text] [Related]
13. Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Gotink KJ; Rovithi M; de Haas RR; Honeywell RJ; Dekker H; Poel D; Azijli K; Peters GJ; Broxterman HJ; Verheul HM
Cell Oncol (Dordr); 2015 Apr; 38(2):119-29. PubMed ID: 25665527
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
15. Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats?
Kiykac Altinbas S; Tapisiz OL; Cavkaytar S; Simsek G; Oguztuzun S; Goktolga U
Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():7-12. PubMed ID: 25462212
[TBL] [Abstract][Full Text] [Related]
16. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis?
Bayoglu Tekin Y; Guven S; Kirbas A; Kalkan Y; Tumkaya L; Guvendag Guven ES
Eur J Obstet Gynecol Reprod Biol; 2015 Jan; 184():1-6. PubMed ID: 25462211
[TBL] [Abstract][Full Text] [Related]
17. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Elsner A; Lange F; Fitzner B; Heuschkel M; Krause BJ; Jaster R
World J Gastroenterol; 2014 Jun; 20(24):7914-25. PubMed ID: 24976727
[TBL] [Abstract][Full Text] [Related]
18. Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
French KJ; Coatney RW; Renninger JP; Hu CX; Gales TL; Zhao S; Storck LM; Davis CB; McSurdy-Freed J; Chen E; Frazier KS
Toxicol Pathol; 2010 Aug; 38(5):691-702. PubMed ID: 20616376
[TBL] [Abstract][Full Text] [Related]
19. The effects of sunitinib on endometriosis.
Pala HG; Erbas O; Pala EE; Artunc Ulkumen B; Akman L; Akman T; Oltulu F; Yavasoglu A
J Obstet Gynaecol; 2015 Feb; 35(2):183-7. PubMed ID: 25093747
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]